|1.||Thorlacius, Henrik: 6 articles (05/2015 - 06/2009)|
|2.||Jankov, Robert P: 5 articles (06/2015 - 02/2008)|
|3.||Koizumi, Noriko: 4 articles (09/2015 - 07/2011)|
|4.||Okumura, Naoki: 4 articles (09/2015 - 07/2011)|
|5.||Kinoshita, Shigeru: 4 articles (09/2015 - 07/2011)|
|6.||Kantores, Crystal: 4 articles (06/2015 - 02/2008)|
|7.||McNamara, Patrick J: 4 articles (06/2015 - 02/2008)|
|8.||Filippi, Sandra: 4 articles (05/2014 - 05/2007)|
|9.||Morelli, Annamaria: 4 articles (05/2014 - 05/2007)|
|10.||Maggi, Mario: 4 articles (05/2014 - 05/2007)|
09/01/2013 - "Finally, inactivation of RhoA signaling in the dKO mice with Y-27632 improved muscle regeneration and reduced the expression of BMPs, inflammation, HO, and intramyocellular lipid accumulation in both skeletal and cardiac muscle. "
07/01/2008 - "The present study addresses the effects of pretreatment with inhaled Y-27632 on the severity of the allergen-induced EAR and LAR, the development of AHR after these reactions, and airway inflammation. "
01/01/2015 - "Y-27632 is associated with corticosteroid-potentiated control of pulmonary remodeling and inflammation in guinea pigs with chronic allergic inflammation."
05/01/2003 - "Oral administration of Y-27632 in rats significantly reduced the colonic inflammation. "
11/01/2009 - "The Rho/ROCK pathway plays an important role in the progression of CAN, and specific inhibition of Rho activity by Y-27632 showed favorable effects on blocking renal interstitial inflammation and fibrosis, thus efficiently retarding the development of CAN, which might provide us with a novel strategy to improve long-term renal graft survival."
12/01/2003 - "Accordingly, during hypoxia, an ROK inhibitor, Y27632, was less effective in relaxing ET-1-precontracted strips. "
08/01/2011 - "Protective effects of Y-27632 on hypoxia/reoxygenation-induced intestinal injury in newborn rats."
05/01/2015 - "In normoxic PA, KMUP-1A/Y27632 (10μM) increased eNOS and reduced ROCK II. ROCK II/reactive oxidative species was increased and eNOS was reduced after long-term hypoxia for 21 days. "
12/01/2010 - "To test these hypotheses, NO production and endothelial barrier function were determined in fetal PAEC under baseline hypoxia and following exposure to normoxia with and without treatment with Y-27632, a specific pharmacological inhibitor of ROCK. "
03/01/2009 - "THG1603 and Y-27632 treatment also attenuated the adverse effects of hypoxia on RGC-5 neurite outgrowth, and their intravitreal administration prevented OIR-induced RGC loss. "
|3.||Muscle Spasticity (Spastic)
08/04/2000 - "The topical application of Y-27632, a specific inhibitor of Rho-kinase, to the exposed spastic basilar artery on day 7 induced a dose-dependent dilation, and the intensities of vasospasm and the phosphorylation of MBS and MLC were simultaneously decreased by 10 micromol/L Y-27632, although the decrease in MBS phosphorylation was more marked than the decrease in MLC phosphorylation. "
06/01/2002 - "However, relaxations to Y-27632 were not significantly greater in endothelin-1 constricted spastic vessels initially relaxed with the endothelin converting enzyme inhibitor, phosphoramidon, as compared to endothelin-1 constricted control vessels. "
03/21/2000 - "Western blot analysis showed that during the serotonin-induced contractions, the extent of phosphorylation of the myosin-binding subunit of myosin phosphatase (MBS), one of the major substrates of Rho-kinase, was significantly greater in the spastic than in the control segment and that the increase in MBS phosphorylations was also markedly inhibited by Y-27632. "
02/01/2003 - "The present study examined whether Y-27632 could provide a beneficial effect on hepatic ischemia/reperfusion (I/R)-induced injury through the attenuation of microcirculatory disturbance. "
12/01/2010 - "Administration of Y-27632 (1 μM) before ischemia and during the first 10 min of reperfusion resulted in complete recovery of cardiac function. "
01/01/2008 - "Cell loss of the GCL and thinning of the IPL were significantly attenuated when 100 nmol Y-27632 was administered within three hours of the induction of ischemia. "
11/28/2004 - "The ischemia/reperfusion-induced renal dysfunction was also overcome by postischemic treatment with Y-27632 at 100 microg/kg, i.p. "
02/15/2004 - "In addition, Y-27632 decreased ischemia/reperfusion-induced accumulation of neutrophils in the heart by 45% (P<0.01). "
01/01/2014 - "Y-27632 (1) inhibited the migration of inflammatory cells into the alveolar space, (2) decreased the production of TNF-α, and (3) attenuated the edema after LTX. "
01/01/2014 - "Pretreatment of the donor lungs and recipient rats with Y-27632 prominently suppressed the post-LTX edema, while the permeability index was only slightly decreased. "
06/01/2005 - "Pretreatment with Y-27632 attenuated both lung edema and neutrophil emigration after LPS. "
11/01/2014 - "To study the effects of inhibiting ROCKs using two known inhibitors, Y27632 and HA1077 (fasudil), administered locally, on nociception and paw edema in rats. "
04/01/2013 - "In addition to the animal study findings, the clinical study findings showed that Y-27632 eye drops effectively improved corneal edema of corneal endothelial dysfunction patients with central edema. "
|2.||fasudil (AT 877)
|3.||Ophthalmic Solutions (Eye Drops)
|6.||Protein Kinases (Protein Kinase)
|7.||Myosin Light Chains (Myosin Essential Light Chain)
|8.||Actins (F Actin)
|9.||Hydroxyproline (4 Hydroxyproline)
|5.||Drug Therapy (Chemotherapy)